Skip to Content

Fortrea Holdings Inc FTRE

Morningstar Rating
$23.01 −0.18 (0.78%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Positive Long-Term Outlook Despite Near-Term Headwinds for Narrow-Moat Fortrea

Fortrea is a global, late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. Fortrea has a lengthy, 30-year history dating to the 1990s, originally part of Corning Incorporated's pharmaceutical services business. In 1997, Corning spun off this segment, which was named Covance. In 2015, Laboratory Corporation of America Holdings, or LabCorp, acquired Covance for $6.1 billion.

Price vs Fair Value

FTRE is trading at a 183% premium.
Price
$23.20
Fair Value
$86.80
Uncertainty
High
1-Star Price
$94.32
5-Star Price
$39.60
Economic Moat
Dlxlhc
Capital Allocation
Jknlbgz

Bulls Say, Bears Say

Bulls

Fortrea is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies.

Bears

There are potential operational risks associated with Fortrea functioning as a newly independent company post its spinoff from LabCorp.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FTRE is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$23.19
Day Range
$22.9523.44
52-Week Range
$22.1741.00
Bid/Ask
$22.95 / $23.02
Market Cap
$2.06 Bil
Volume/Avg
104,341 / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
24.82
Price/Sales
0.69
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
16,000

Competitors

Valuation

Metric
FTRE
IQV
MEDP
Price/Earnings (Normalized)
24.8220.2941.35
Price/Book Value
1.306.0018.72
Price/Sales
0.692.576.57
Price/Cash Flow
69.5216.3036.35
Price/Earnings
FTRE
IQV
MEDP

Financial Strength

Metric
FTRE
IQV
MEDP
Quick Ratio
1.260.780.72
Current Ratio
1.470.880.78
Interest Coverage
0.083.00
Quick Ratio
FTRE
IQV
MEDP

Profitability

Metric
FTRE
IQV
MEDP
Return on Assets (Normalized)
−0.91%7.28%21.26%
Return on Equity (Normalized)
−2.29%31.85%67.47%
Return on Invested Capital (Normalized)
1.26%12.78%49.10%
Return on Assets
FTRE
IQV
MEDP
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
GscjbywwGmp$636.3 Bil
Vertex Pharmaceuticals Inc
VRTX
LhtbflkbStzxgp$124.4 Bil
Regeneron Pharmaceuticals Inc
REGN
MkyfmfccGntcrv$115.9 Bil
Moderna Inc
MRNA
BqbnnlsvNmhh$44.6 Bil
Alnylam Pharmaceuticals Inc
ALNY
BnmrtjnsFbjtjr$32.3 Bil
argenx SE ADR
ARGX
DjygcdqldPhbff$25.8 Bil
BioNTech SE ADR
BNTX
DsckwdlzCvh$19.4 Bil
Biomarin Pharmaceutical Inc
BMRN
PwskjhyFyslpdk$15.7 Bil
United Therapeutics Corp
UTHR
FnfvbxhnCgyk$14.1 Bil
Royalty Pharma PLC Class A
RPRX
VhtbxfqsGdynn$11.6 Bil

Sponsor Center